Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
33 studies found for:    Open Studies | "Plasmacytoma"
Show Display Options
Rank Status Study
21 Recruiting Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Conditions: Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: busulfan;   Drug: cyclophosphamide;   Biological: Stem cell infusion;   Radiation: Total body irradiation
22 Unknown  High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Biological: pegfilgrastim;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation
23 Unknown  Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: dexamethasone
24 Unknown  High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: cyclophosphamide;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation
25 Unknown  Study of DNA Samples From Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Intervention: Genetic: polymorphism analysis
26 Unknown  Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Genetic: gene expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Other: platelet aggregation test
27 Unknown  Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: hydroxychloroquine;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Other: mass spectrometry;   Other: pharmacological study;   Procedure: biopsy
28 Unknown  Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
Condition: Cancer
Interventions: Drug: ketamine hydrochloride;   Other: pharmacogenomic studies;   Other: questionnaire administration;   Procedure: assessment of therapy complications;   Procedure: quality-of-life assessment
29 Unknown  Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: CX-4945
30 Recruiting Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab;   Drug: VELCADE (Bortezomib);   Drug: Dexamethasone
31 Recruiting Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy
Condition: Carcinoma
Intervention:
32 Recruiting Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Conditions: Hematologic Disease;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome;   Myeloproliferative Disorder
Intervention: Procedure: Stem cell transplantation
33 Recruiting Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma Following Lenalidomide Plus Low Dose Dexamethasone as Second Line Treatment.
Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide;   Drug: Dexamethasone

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-33) Next Page   
Indicates status has not been verified in more than two years